Nabriva Therapeutics AG – (NASDAQ:NBRV)‘s stock had its “outperform” rating restated by investment analysts at Wedbush in a report issued on Wednesday, AnalystRatingsNetwork.com reports. They currently have a $17.00 target price on the stock. Wedbush’s price objective would indicate a potential upside of 86.81% from the company’s previous close.
A number of hedge funds have made changes to their positions in the company. Boxer Capital LLC acquired a new stake in shares of Nabriva Therapeutics AG – during the fourth quarter worth approximately $1,688,000. Novo A S raised its stake in shares of Nabriva Therapeutics AG – by 0.9% in the fourth quarter. Novo A S now owns 874,985 shares of the company’s stock worth $8,417,000 after buying an additional 7,858 shares during the last quarter. United Services Automobile Association raised its stake in shares of Nabriva Therapeutics AG – by 21.0% in the fourth quarter. United Services Automobile Association now owns 123,440 shares of the company’s stock worth $1,179,000 after buying an additional 21,440 shares during the last quarter. EcoR1 Capital LLC raised its stake in shares of Nabriva Therapeutics AG – by 0.4% in the fourth quarter. EcoR1 Capital LLC now owns 838,680 shares of the company’s stock worth $7,931,000 after buying an additional 3,150 shares during the last quarter. Finally, Acuta Capital Partners LLC raised its stake in shares of Nabriva Therapeutics AG – by 17.5% in the fourth quarter. Acuta Capital Partners LLC now owns 412,747 shares of the company’s stock worth $3,971,000 after buying an additional 61,486 shares during the last quarter.
A number of other research firms have also weighed in on NBRV. Zacks Investment Research lowered Nabriva Therapeutics AG – from a “hold” rating to a “sell” rating in a research note on Saturday, January 9th. Gabelli assumed coverage on Nabriva Therapeutics AG – in a research note on Wednesday, January 27th. They set a “buy” rating and a $14.00 price objective for the company. One analyst has rated the stock with a sell rating and five have given a buy rating to the company. The stock presently has a consensus rating of “Buy” and an average price target of $17.40.
Nabriva Therapeutics AG is an Austria-based clinical-stage biopharmaceutical company engaged in the research and development of antibiotics to treat infections. Its product pipeline includes lefamulin, a Phase Two plueromutilin antibiotic in intravenous (NASDAQ:NBRV) and oral formulations for the treatment of community-acquired bacterial pneumonia (CABP), and BC-7013, a Phase One topical pleuromutilin treatment for Gram-positive infections, including uncomplicated skin and skin structure infections (uSSSSIs).
